Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
TriSalus Life Sciences, Inc. - Common Stock
(NQ:
TLSI
)
5.680
+0.030 (+0.53%)
Streaming Delayed Price
Updated: 11:19 AM EST, Feb 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
23,512
Open
5.580
Bid (Size)
5.660 (1)
Ask (Size)
5.820 (2)
Prev. Close
5.650
Today's Range
5.530 - 5.785
52wk Range
3.500 - 10.42
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
TriSalus Life Sciences Announces Key Appointments to Board of Directors
February 03, 2025
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
February 03, 2025
From
TriSalus Life Sciences
Via
Business Wire
Performance
YTD
+14.06%
+14.06%
1 Month
+16.87%
+16.87%
3 Month
+54.77%
+54.77%
6 Month
-0.26%
-0.26%
1 Year
-38.59%
-38.59%
More News
Read More
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
January 23, 2025
From
TriSalus Life Sciences
Via
Business Wire
A Look Ahead: TriSalus Life Sciences's Earnings Forecast
November 13, 2024
Via
Benzinga
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
January 09, 2025
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Announces Leadership Changes
January 08, 2025
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
November 14, 2024
From
TriSalus Life Sciences
Via
Business Wire
Earnings Scheduled For November 14, 2024
November 14, 2024
Via
Benzinga
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday
November 11, 2024
Via
Benzinga
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
November 11, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
November 07, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
October 31, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
October 14, 2024
From
TriSalus Life Sciences
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 07, 2024
Via
Benzinga
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board
September 26, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
September 23, 2024
From
TriSalus Life Sciences
Via
Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024
August 15, 2024
Via
InvestorPlace
TriSalus Reports Q2 2024 Financial Results and Business Update
August 15, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
August 01, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
July 01, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
June 26, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
June 03, 2024
From
TriSalus Life Sciences
Via
Business Wire
Crude Oil Rises 1%; Verastem Shares Slide
May 24, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 24, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.